Immunostimulatory therapy with anti-CD3 monoclonal antibodies and recombinant interleukin-2: Heightened in vivo expression of mRNA encoding cytotoxic attack molecules and immunoregulatory cytokines and regression of murine renal cell carcinoma

Tomohiko Asano, Ashwani Khanna, Milagros Lagman, Baogui Li, Manikkam Suthanthiran

Research output: Contribution to journalArticle

7 Citations (Scopus)


The response rate to IL-2 immunotherapy, currently used in the treatment of metastatic renal cell cancer, is limited. Based on our earlier demonstration that a combined regimen of monoclonal antibodies directed at the T cell surface protein CD3 (anti-CD3 mAbs) and IL-2 is synergistic in constraining tumor progression in a murine fibrosarcoma hepatic metastasis model, we have explored the efficacy of an anti-CD3 mAbs plus IL-2 regimen in a murine renal cell cancer model. Our studies demonstrate that a regimen of anti-CD3 mAbs plus IL-2 is superior to treatment with anti-CD3 mAbs alone or IL-2 alone in reducing the number of pulmonary metastases and in prolonging survival. Moreover, the efficacious regimen is associated with heightened intrapulmonary expression of mRNA encoding cytotoxic attack molecules (perforin, granzyme B) and immunoregulatory cytokines (IL-4, IL-10 and IFN- γ).

Original languageEnglish
Pages (from-to)2396-2401
Number of pages6
JournalJournal of Urology
Issue number6
Publication statusPublished - Jun 1997



  • anti-CD3 mAbs
  • immunotherapy
  • interleukin-2
  • renal cancer

ASJC Scopus subject areas

  • Urology

Cite this